Drug Profile
Research programme: immunotherapies - Syntara
Alternative Names: Immune therapies - Midatech/Immunotope; Immune therapies - SyntaraLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Syntara
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Viral-infections in USA
- 13 Jul 2010 Early research in Cancer in USA (unspecified route)